M
6.48
0.15 (2.37%)
| Previous Close | 6.33 |
| Open | 6.32 |
| Volume | 271,048 |
| Avg. Volume (3M) | 585,703 |
| Market Cap | 520,767,808 |
| Price / Earnings (Forward) | 1.61 |
| Price / Sales | 13.81 |
| Price / Book | 15.73 |
| 52 Weeks Range | |
| Earnings Date | 11 Aug 2025 - 15 Aug 2025 |
| Operating Margin (TTM) | -2,159.71% |
| Diluted EPS (TTM) | -2.31 |
| Quarterly Revenue Growth (YOY) | 176.30% |
| Total Debt/Equity (MRQ) | 244.35% |
| Current Ratio (MRQ) | 1.52 |
| Operating Cash Flow (TTM) | -104.58 M |
| Levered Free Cash Flow (TTM) | -53.25 M |
| Return on Assets (TTM) | -37.28% |
| Return on Equity (TTM) | -216.14% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | MeiraGTx Holdings plc | Bullish | Bullish |
AIStockmoo Score
0.6
| Analyst Consensus | 3.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 2.0 |
| Average | 0.63 |
|
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 24.27% |
| % Held by Institutions | 60.04% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Perceptive Advisors Llc | 31 Mar 2025 | 12,581,103 |
| Sanofi | 31 Mar 2025 | 12,197,737 |
| Johnson & Johnson | 31 Mar 2025 | 6,641,064 |
| Adage Capital Partners Gp, L.L.C. | 31 Mar 2025 | 5,634,578 |
| Prosight Management, Lp | 31 Mar 2025 | 3,691,546 |
| 683 Capital Management, Llc | 31 Mar 2025 | 2,575,000 |
| Rubric Capital Management Lp | 31 Mar 2025 | 1,776,321 |
| Knoll Capital Management, Llc | 31 Mar 2025 | 1,250,000 |
| J. Goldman & Co Lp | 31 Mar 2025 | 1,158,761 |
| Woodline Partners Lp | 31 Mar 2025 | 803,546 |
| Erste Asset Management Gmbh | 31 Mar 2025 | 789,702 |
| Royce & Associates Lp | 31 Mar 2025 | 607,839 |
| 52 Weeks Range | ||
| Median | 35.00 (440.12%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Chardan Capital | 14 May 2025 | 35.00 (440.12%) | Buy | 4.64 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| HARRIS KEITH R. | - | - | 0 | 0 |
| Aggregate Net Quantity | 0 | |||
| Aggregate Net Value ($) | 0 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| HARRIS KEITH R. | Director | 06 Jun 2025 | Option execute | 75,000 | - | - |
| Date | Type | Details |
|---|---|---|
| 13 May 2025 | Announcement | MeiraGTx Reports First Quarter 2025 Financial and Operational Results |
| 13 May 2025 | Announcement | MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting |
| 09 May 2025 | Announcement | MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson’s Disease |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |